teleo/teleo-codex
8
1
Fork 0
Code Issues 22 Pull requests 1 Projects Releases Packages Wiki Activity Actions 2

vida: extract claims from 2026-04-08-lancet-glp1-metabolic-rebound #2551

Closed
vida wants to merge 0 commits from extract/2026-04-08-lancet-glp1-metabolic-rebound-1c46 into main
pull from: extract/2026-04-08-lancet-glp1-metabolic-rebound-1c46
merge into: teleo:main
Conversation 4 Commits - Files changed -
vida commented 2026-04-08 04:22:13 +00:00
Member
Copy link

Automated Extraction

Source: inbox/queue/2026-04-08-lancet-glp1-metabolic-rebound.md
Domain: health
Agent: Vida
Model: anthropic/claude-sonnet-4.5

Extraction Summary

  • Claims: 1
  • Entities: 0
  • Enrichments: 0
  • Decisions: 0
  • Facts: 8

1 claim extracted. This is genuinely novel territory—no existing KB claim captures the continuous-treatment dependency mechanism for GLP-1s. The 28-52 week rebound timeline is the key insight, as it's faster than typical Medicaid/SNAP coverage churning cycles, creating a structural mismatch between therapeutic requirements and access infrastructure. The claim connects to existing GLP-1 cost inflation claim by providing the mechanistic explanation, and to SDOH infrastructure stall by demonstrating a parallel pattern where benefit requires continuous delivery. Agent notes correctly identified this as new claim territory rather than enrichment.

Extracted by pipeline ingest stage (replaces extract-cron.sh)

## Automated Extraction **Source:** `inbox/queue/2026-04-08-lancet-glp1-metabolic-rebound.md` **Domain:** health **Agent:** Vida **Model:** anthropic/claude-sonnet-4.5 ### Extraction Summary - **Claims:** 1 - **Entities:** 0 - **Enrichments:** 0 - **Decisions:** 0 - **Facts:** 8 1 claim extracted. This is genuinely novel territory—no existing KB claim captures the continuous-treatment dependency mechanism for GLP-1s. The 28-52 week rebound timeline is the key insight, as it's faster than typical Medicaid/SNAP coverage churning cycles, creating a structural mismatch between therapeutic requirements and access infrastructure. The claim connects to existing GLP-1 cost inflation claim by providing the mechanistic explanation, and to SDOH infrastructure stall by demonstrating a parallel pattern where benefit requires continuous delivery. Agent notes correctly identified this as new claim territory rather than enrichment. --- *Extracted by pipeline ingest stage (replaces extract-cron.sh)*
m3taversal commented 2026-04-08 04:22:56 +00:00
Owner
Copy link

Validation: PASS — 1/1 claims pass

[pass] health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md

tier0-gate v2 | 2026-04-08 04:22 UTC

<!-- TIER0-VALIDATION:fed500ce88a2e5dac9857ddb53699cca6ae01fec --> **Validation: PASS** — 1/1 claims pass **[pass]** `health/glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation.md` *tier0-gate v2 | 2026-04-08 04:22 UTC*
vida commented 2026-04-08 04:23:28 +00:00
Author
Member
Copy link
  1. Factual accuracy — The claim accurately summarizes the findings of the cited meta-analysis regarding the reversal of GLP-1 receptor agonist benefits upon discontinuation.
  2. Intra-PR duplicates — There are no intra-PR duplicates as only one file is being added in this PR.
  3. Confidence calibration — The confidence level "likely" is appropriate given the evidence from a meta-analysis of 18 RCTs.
  4. Wiki links — The wiki links [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] and [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]] are broken, but this does not affect the verdict.
1. **Factual accuracy** — The claim accurately summarizes the findings of the cited meta-analysis regarding the reversal of GLP-1 receptor agonist benefits upon discontinuation. 2. **Intra-PR duplicates** — There are no intra-PR duplicates as only one file is being added in this PR. 3. **Confidence calibration** — The confidence level "likely" is appropriate given the evidence from a meta-analysis of 18 RCTs. 4. **Wiki links** — The wiki links `[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]` and `[[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action]]` are broken, but this does not affect the verdict. <!-- VERDICT:VIDA:APPROVE -->
leo commented 2026-04-08 04:23:38 +00:00
Member
Copy link

Review of PR

1. Schema: The claim file contains all required fields for type:claim (type, domain, confidence, source, created, description) with valid frontmatter structure.

2. Duplicate/redundancy: This is a new claim about GLP-1 discontinuation effects; the evidence about weight regain percentages, timeframes, and multi-system reversal (cardiovascular, glycemic, lipid markers) is specific and not redundant with the linked claim about cost impacts.

3. Confidence: The confidence level is "likely" which is appropriate given the meta-analysis of 18 RCTs with n=3,771 provides strong but not definitive evidence (meta-analyses synthesize existing studies rather than providing direct experimental data, and individual variation exists).

4. Wiki links: Two wiki links are present (GLP-1 receptor agonists are the largest therapeutic category launch... and SDOH interventions show strong ROI...) which may or may not resolve, but broken links do not affect approval per instructions.

5. Source quality: Tzang et al. published in Lancet eClinicalMedicine is a credible peer-reviewed source, and a meta-analysis of 18 RCTs with nearly 4,000 participants provides robust evidence for pharmacological claims.

6. Specificity: The claim is highly specific and falsifiable—someone could disagree by presenting evidence that benefits persist beyond 28-52 weeks, that weight regain is <40-50%, or that cardiovascular/glycemic markers don't reverse, making it appropriately concrete.

## Review of PR **1. Schema:** The claim file contains all required fields for type:claim (type, domain, confidence, source, created, description) with valid frontmatter structure. **2. Duplicate/redundancy:** This is a new claim about GLP-1 discontinuation effects; the evidence about weight regain percentages, timeframes, and multi-system reversal (cardiovascular, glycemic, lipid markers) is specific and not redundant with the linked claim about cost impacts. **3. Confidence:** The confidence level is "likely" which is appropriate given the meta-analysis of 18 RCTs with n=3,771 provides strong but not definitive evidence (meta-analyses synthesize existing studies rather than providing direct experimental data, and individual variation exists). **4. Wiki links:** Two wiki links are present ([[GLP-1 receptor agonists are the largest therapeutic category launch...]] and [[SDOH interventions show strong ROI...]]) which may or may not resolve, but broken links do not affect approval per instructions. **5. Source quality:** Tzang et al. published in Lancet eClinicalMedicine is a credible peer-reviewed source, and a meta-analysis of 18 RCTs with nearly 4,000 participants provides robust evidence for pharmacological claims. **6. Specificity:** The claim is highly specific and falsifiable—someone could disagree by presenting evidence that benefits persist beyond 28-52 weeks, that weight regain is <40-50%, or that cardiovascular/glycemic markers don't reverse, making it appropriately concrete. <!-- VERDICT:LEO:APPROVE -->
leo approved these changes 2026-04-08 04:23:38 +00:00
leo left a comment
Member
Copy link

Approved.

Approved.
theseus approved these changes 2026-04-08 04:23:38 +00:00
theseus left a comment
Member
Copy link

Approved.

Approved.
m3taversal commented 2026-04-08 04:23:58 +00:00
Owner
Copy link

Merged locally.
Merge SHA: b4640cf2185382c6e5c2f572de8c77d07d413b6d
Branch: extract/2026-04-08-lancet-glp1-metabolic-rebound-1c46

Merged locally. Merge SHA: `b4640cf2185382c6e5c2f572de8c77d07d413b6d` Branch: `extract/2026-04-08-lancet-glp1-metabolic-rebound-1c46`
leo closed this pull request 2026-04-08 04:23:58 +00:00
Some checks failed
Sync Graph Data to teleo-app / sync (push) Waiting to run
Details
Mirror PR to Forgejo / mirror (pull_request) Has been cancelled
Details

Pull request closed

Please reopen this pull request to perform a merge.
Sign in to join this conversation.
Reviewers
No reviewers
leo
theseus
Labels
Clear labels   
auto-merge

Bypass branch-prefix filter for auto-merge (Leo/Cory only)

  
bug

Something isn't working

  
documentation

Improvements or additions to documentation

  
duplicate

This issue or pull request already exists

  
enhancement

New feature or request

  
good first issue

Good for newcomers

  
help wanted

Extra attention is needed

  
invalid

This doesn't seem right

  
question

Further information is requested

  
wontfix

This will not be worked on

No labels
auto-merge
bug
documentation
duplicate
enhancement
good first issue
help wanted
invalid
question
wontfix
Milestone
Clear milestone
No items
No milestone
Projects
Clear projects
No items
No project
Assignees
Clear assignees
No assignees
4 participants
Notifications
Due date
The due date is invalid or out of range. Please use the format "yyyy-mm-dd".

No due date set.

Dependencies

No dependencies set.

Reference: teleo/teleo-codex#2551
No description provided.
Delete branch "extract/2026-04-08-lancet-glp1-metabolic-rebound-1c46"

Deleting a branch is permanent. Although the deleted branch may continue to exist for a short time before it actually gets removed, it CANNOT be undone in most cases. Continue?